Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Study assesses cancers in children exposed to medical imaging

Ten percent of pediatric blood and bone marrow cancers may have stemmed from radiation exposure, according to a study led by UC San Francisco and UC Davis.

September 26, 2025

Vol.51 No.35

Conversation with The Cancer Letter Podcast

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.

August 14, 2025

Vol.51 No.32

By Paul Goldberg and Sara Willa Ernst

In Brief

Leukemia & Lymphoma Society renamed Blood Cancer United

The Leukemia & Lymphoma Society is becoming Blood Cancer United on August 28 in advance of Blood Cancer Awareness Month in September.

August 01, 2025

Vol.51 No.30

Clinical Roundup

IGRT shows no reduction in serious infections for patients with CLL

Regular treatment with immunoglobulin replacement therapy in patients with chronic lymphocytic leukemia was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

August 01, 2025

Vol.51 No.30

Drugs & Targets

China’s NMPA approves lisaftoclax for CLL or SLL

The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Genetic mutations link could lead to new therapies for AML

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Memorial Sloan Kettering Cancer Center in New York have found a link between two genetic mutations in a subtype of acute myeloid leukemia, which could lead to new ways to treat the disease.

April 25, 2025

Vol.51 No.16

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

YOU MAY BE INTERESTED IN

Study assesses cancers in children exposed to medical imaging

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group

Leukemia & Lymphoma Society renamed Blood Cancer United

IGRT shows no reduction in serious infections for patients with CLL

China’s NMPA approves lisaftoclax for CLL or SLL

Genetic mutations link could lead to new therapies for AML

Renew today!

Subscriber content

Never miss an issue!

Login

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

YOU MAY BE INTERESTED IN

Study assesses cancers in children exposed to medical imaging

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSUBrian Druker returns to executive role as president of the new Knight Cancer Group

Leukemia & Lymphoma Society renamed Blood Cancer United

IGRT shows no reduction in serious infections for patients with CLL

China’s NMPA approves lisaftoclax for CLL or SLL

Genetic mutations link could lead to new therapies for AML

Never miss an issue!

Login

Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group